Navigation Links
Researchers discover a missing link in signals contributing to neurodegeneration
Date:5/9/2013

In many neurodegenerative diseases the neurons of the brain are over-stimulated and this leads to their destruction. After many failed attempts and much scepticism this process was finally shown last year to be a possible basis for treatment in some patients with stroke. But very few targets for drugs to block this process are known.

In a new highly detailed study, researchers have discovered a previously missing link between over-stimulation and destruction of brain tissue, and shown that this might be a target for future drugs. This research, led by the A. I. Virtanen Institute at the University of Eastern Finland in collaboration with scientists from Lausanne University Hospital, University of Lausanne and the company Xigen Pharma AG, was published in the Journal of Neuroscience.

What is this missing link? We have known for years that over-stimulated neurons produce nitric oxide molecules. Although this can activate a signal for destruction of cells, the small amount of nitric oxide produced cannot alone explain the damage to the brain. The team now show that a protein called NOS1AP links the nitric oxide that is produced to the damage that results. NOS1AP binds an initiator of cell destruction called MKK3 and also moves within the cell to the source of nitric oxide when cells are over-activated. The location of these proteins in cells causes them to convert the over-stimulation signal into a cell destruction response. The team designed a chemical that prevents NOS1AP from binding the source of nitric oxide. This reduces the cell destruction response in cells of the brain and as a result it limits brain lesions in rodents.

This translational research was funded mainly by the Academy of Finland, the European Union and the University of Eastern Finland and used the recently developed high-throughput imaging facilities at the A. I. Virtanen Institute. The researchers hope that continuation of their work could lead to improved treatments for diseases such as stroke, epilepsy and chronic conditions like Alzheimer's disease. As NOS1AP is associated with schizophrenia, diabetes and sudden cardiac death, future research in this area may assist the treatment of a wider range of diseases.


'/>"/>

Contact: Michael Courtney
mjczmjc@gmail.com
358-403-553-663
University of Eastern Finland
Source:Eurekalert

Related biology news :

1. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
2. UC Santa Barbara researchers discover genetic link between visual pathways of hydras and humans
3. Researchers attempt to solve problems of antibiotic resistance and bee deaths in one
4. UNH researchers find African farmers need better climate change data to improve farming practices
5. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
6. Researchers uncover molecular pathway through which common yeast becomes fungal pathogen
7. Researchers print live cells with a standard inkjet printer
8. Columbia Engineering and Penn researchers increase speed of single-molecule measurements
9. Researchers reveal how a single gene mutation leads to uncontrolled obesity
10. Researchers discover novel therapy for Crohns disease
11. New paper by Notre Dame researchers describes method for cleaning up nuclear waste
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2016)... Minn. , Nov. 22, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... Medical LiveWire Healthcare and Life Sciences Awards ... award caps off an unprecedented year of recognition and ... trials for over 15 years. iMedNet ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Public Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is ... analysis for Private Biobanks shows the highest Compounded Annual Growth ... region during the analysis period 2014-2020. ... CAGR of 9.95% followed by Europe ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016 Amgen (NASDAQ: ... ) today announced the submission of a Marketing Authorization Application ... a biosimilar candidate to Avastin ® (bevacizumab). The companies ... to the EMA. "The submission of ABP ... seeks to expand our oncology portfolio," said Sean E. ...
(Date:12/2/2016)... ... , ... ACEA Biosciences, Inc. announced today that it will be presenting updated ... World Conference on Lung Cancer 2016, taking place in Vienna, Austria December 3rd-8th. ... for AC0010 in patients with advanced non-small cell lung cancer harboring the EGFR T790M ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... (CSS) and the popularity of US Single Day Events (SDE) to organize a ... Summer 2018, in Raleigh, NC. Topics of the pharmaceutical and life sciences industry ...
(Date:12/2/2016)... IL (PRWEB) , ... December 01, 2016 , ... ... to congratulate long-term client Nanowear on their recent FDA Class II 510(k) clearance ... cleared a significant hurdle in commercializing remote cardiac monitoring devices that rely on ...
Breaking Biology Technology: